Literature DB >> 26428377

Epstein-Barr Virus Lytic Cycle Reactivation.

Jessica McKenzie1, Ayman El-Guindy2.   

Abstract

Epstein-Barr virus, which mainly infects B cells and epithelial cells, has two modes of infection: latent and lytic. Epstein-Barr virus infection is predominantly latent; however, lytic infection is detected in healthy seropositive individuals and becomes more prominent in certain pathological conditions. Lytic infection is divided into several stages: early gene expression, DNA replication, late gene expression, assembly, and egress. This chapter summarizes the most recent progress made toward understanding the molecular mechanisms that regulate the different lytic stages leading to production of viral progeny. In addition, the chapter highlights the potential role of lytic infection in disease development and current attempts to purposely induce lytic infection as a therapeutic approach.

Entities:  

Keywords:  BZLF1; DNA methylation; EBV DNA replication; EBV-associated diseases; Lytic infection; Oncolytic

Mesh:

Year:  2015        PMID: 26428377     DOI: 10.1007/978-3-319-22834-1_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  36 in total

Review 1.  Herpesvirus-bacteria synergistic interaction in periodontitis.

Authors:  Casey Chen; Pinghui Feng; Jørgen Slots
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

2.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

3.  Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.

Authors:  Jaeyeun Lee; John G Kosowicz; S Diane Hayward; Prashant Desai; Jennifer Stone; Jae Myun Lee; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1.

Authors:  Mei-Tzu Su; Ya-Ting Wang; Yen-Ju Chen; Su-Fang Lin; Ching-Hwa Tsai; Mei-Ru Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 5.  Role of the receptor for activated C kinase 1 during viral infection.

Authors:  Yan Wang; Xiaorong Qiao; Yuhan Li; Qingru Yang; Lulu Wang; Xiaolan Liu; Hua Wang; Hongxing Shen
Journal:  Arch Virol       Date:  2022-06-28       Impact factor: 2.685

Review 6.  Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives.

Authors:  Zbigniew Wyżewski; Matylda Barbara Mielcarska; Karolina Paulina Gregorczyk-Zboroch; Anna Myszka
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

7.  Epstein-Barr virus tegument protein BGLF2 in exosomes released from virus-producing cells facilitates de novo infection.

Authors:  Yoshitaka Sato; Masahiro Yaguchi; Yusuke Okuno; Hanako Ishimaru; Ken Sagou; Somi Ozaki; Takeshi Suzuki; Tomoki Inagaki; Miki Umeda; Takahiro Watanabe; Masahiro Fujimuro; Takayuki Murata; Hiroshi Kimura
Journal:  Cell Commun Signal       Date:  2022-06-21       Impact factor: 7.525

Review 8.  Epstein-Barr virus infection and nasopharyngeal carcinoma.

Authors:  Sai Wah Tsao; Chi Man Tsang; Kwok Wai Lo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

9.  Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in Epstein-Barr virus-positive B lymphocytes.

Authors:  Cong Long; Qiu-Bo Xu; Li Ding; Liu Yang; Wei Ji; Feng Gao; Yong Ji
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

10.  Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.

Authors:  Wen-Jie Chen; Wen-Na Xu; Hai-Yun Wang; Xiao-Xia Chen; Xue-Qi Li; Shang-Hang Xie; Dong-Feng Lin; Su-Mei Cao
Journal:  BMC Cancer       Date:  2021-06-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.